{"links":{"html":"https://www.erudio.com/reports/arastep-nct05794906","json":"https://www.erudio.com/reports/arastep-nct05794906.json","markdown":"https://www.erudio.com/reports/arastep-nct05794906.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"arastep-05794906"}},"request":"https://www.erudio.com/contact?report=arastep-05794906"},"offer":{"cited_commentary_sources":17,"verified_hcp_statements":95,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":15,"optional":true,"price_per_verified_person_usd":15,"price_usd":225,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"arastep-nct05794906"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=arastep-05794906","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/arastep-nct05794906","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T16:08:01.119156Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":5,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":4,"title":"Primary endpoint: Radiological progression-free survival (rPFS) by Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) assessed by Blinded independent central review (BICR)"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":13,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":9,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":4,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":1,"title":"Safety and tolerability"},{"claim_count":6,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":5,"coverage":"discussed","id":"A1","source_count":3,"title":"Finite treatment and the two-year rationale"},{"claim_count":18,"coverage":"discussed","id":"A2","source_count":6,"title":"SBRT, systemic therapy and benefit after lesion ablation"},{"claim_count":8,"coverage":"discussed","id":"A3","source_count":4,"title":"PSA kinetics, individualized selection and routine-care patterns"},{"claim_count":12,"coverage":"discussed","id":"A4","source_count":1,"title":"Stage migration, de-escalation and treatment urgency"},{"claim_count":9,"coverage":"discussed","id":"A5","source_count":7,"title":"Imaging access, referral and patient-centered treatment discussions"}],"counts":{"cited_sources":19,"claims_by_expression_type":{"comparison":7,"experience":6,"interpretation":23,"opinion":22,"primary_context":7,"question":7,"restatement":15,"uncertainty":7,"unspecified":1},"claims_by_kind":{"protocol_statement":4,"publication_statement":16,"source_observation":75},"clinician_statements":35,"evidence_units":72,"findings":7,"people_cited":19,"people_identity_verified":15,"people_total":20,"screened_sources":56,"verified_claims":95},"findings_index":[{"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":4,"restated":1,"views":3},"has_counterview":true,"limitations":3,"links":{"context":3,"support":9},"ma_question":true,"named_voices":6,"passages":9,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"PSMA positivity does not settle how much systemic treatment—or how urgently—to give"},{"id":"F2","structure":{"claims":17,"claims_by_group":{"comparisons":2,"experience":1,"questions":5,"restated":2,"views":7},"has_counterview":true,"limitations":3,"links":{"context":2,"support":19},"ma_question":true,"named_voices":5,"passages":13,"sources":5,"sources_by_kind":{"commentary":1,"media":4}},"title":"Local treatment is discussed alongside systemic therapy, while benefit after complete lesion ablation remains open"},{"id":"F3","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":1,"views":4},"has_counterview":true,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":2,"passages":6,"sources":3,"sources_by_kind":{"media":2,"publication":1}},"title":"Two years is presented as a pragmatic middle course, not a proven optimal duration"},{"id":"F4","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":3,"views":7},"has_counterview":true,"limitations":4,"links":{"context":2,"support":15},"ma_question":true,"named_voices":5,"passages":11,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"Optimization can mean more or less treatment, but depends on recognizing risk correctly"},{"id":"F5","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Enzalutamide monotherapy is an alternative with its own benefit–harm trade-offs, not simply less treatment"},{"id":"F6","structure":{"claims":24,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":8,"views":13},"has_counterview":true,"limitations":3,"links":{"context":0,"support":26},"ma_question":true,"named_voices":10,"passages":20,"sources":12,"sources_by_kind":{"commentary":5,"media":5,"publication":1,"registry":1}},"title":"PSMA-era relevance is a perceived strength, but imaging accuracy and clinically meaningful benefit remain separate questions"},{"id":"F7","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":2,"views":5},"has_counterview":true,"limitations":3,"links":{"context":0,"support":11},"ma_question":true,"named_voices":7,"passages":9,"sources":8,"sources_by_kind":{"commentary":4,"media":3,"publication":1}},"title":"Enthusiasm is prospective and explicitly separated from a demonstrated ARASTEP benefit"}],"medical_affairs_question":"What added benefit from darolutamide, after any lesion-directed treatment and over a finite ADT course, would be clinically meaningful enough to justify its burden?","sections":{"analysis":[{"id":"section-1","level":2,"title":"PSMA positivity does not settle systemic intensity or treatment urgency"},{"id":"section-2","level":2,"title":"Local control and systemic risk are not interchangeable"},{"id":"section-3","level":2,"title":"Finite treatment is favored more clearly than any single optimal duration"},{"id":"section-4","level":2,"title":"Risk recognition separates optimization from undertreatment"},{"id":"section-5","level":2,"title":"Hormonal alternatives require explicit benefit–harm counseling"},{"id":"section-6","level":2,"title":"Contemporary imaging improves relevance without validating every treatment inference"},{"id":"section-7","level":2,"title":"Optimism concerns the pending answer, not an observed benefit"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":1},{"id":"F6","shared_claims":4},{"id":"F7","shared_claims":1}],"id":"T1","label":"Primary endpoint: Radiological progression-free survival (rPFS) by Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) assessed by Blinded independent central review (BICR)"},{"findings":[{"id":"F6","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":10}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":3},{"id":"F7","shared_claims":6}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F5","shared_claims":4}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T16:08:01.119156Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T16:20:10Z","record_hash":"0d611f92493de751051dcb49b63cee89476c7f790c124f44e40fcbee44989488","release_hash":"c4ee715782df50d573c476db5b862291957bbbbfeb2b80d42439b0007893fa99","report_id":"erudio-nct05794906","run_id":"2c669909-aeec-4650-857b-0607cc5865b9","schema_version":"5.0","slug":"arastep-05794906","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"ARASTEP asks whether adding darolutamide to ADT delays imaging-detected progression in high-risk biochemical recurrence of prostate cancer with PSMA-positive lesions and negative conventional imaging. Commentary comes from X threads, podcasts and YouTube discussions, including medical oncologists. The discussion turns on whether delaying PSMA-detected progression is clinically meaningful, whether an ARPI adds benefit after complete lesion ablation, and whether two years of hormonal therapy is optimal.","meta_description":"56 sources screened · 95 verified statements (35 from clinicians verified by NPI or staff page) from 19 sources · 7 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-aee3eb36d9819313e6a1","claim-62b3ac4909667ce4058a"],"id":"F2","paraphrase":"A podcast exchange discussing ARASTEP asks whether adding an androgen-receptor pathway inhibitor to ADT benefits patients after radiation to every PSMA-detected oligometastatic lesion.","publication_caveats":["The source does not identify who asks the question about benefit after irradiation."],"source_channel":"podcast","source_date":"2025-05-14","title":"Local treatment is discussed alongside systemic therapy, while benefit after complete lesion ablation remains open"},{"cited_claim_ids":["claim-9036049fff09f15c3829","claim-f446634f9465bbc61cb3"],"id":"F1","paraphrase":"An X thread discussing ARASTEP asks how much systemic intensification is needed in PSMA-positive recurrence and whether every PSMA-positive lesion reflects active cancer.","publication_caveats":["These are post dates for the thread; the individual questions are not separately dated."],"source_channel":"x_thread","source_date":"2025-12-07","title":"PSMA positivity does not settle how much systemic treatment—or how urgently—to give"}]},"publication":{"approved_at":"2026-10-31T16:20:10Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":56},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a question about individualizing novel antiandrogen selection according to cardiac and neurological risk.","Not yet captured in this edition: a view on individualized anti-androgen selection, practical ease of use, and patient discussion of benefits and adverse effects.","Not yet captured in this edition: a view on treatment benefits, survival expectations and comparative toxicities of systemic options for high-risk biochemical recurrence.","Not yet captured in this edition: a view on efficacy, survival qualifications and comparative toxicity when choosing systemic treatment for high-risk biochemical recurrence.","Not yet captured in this edition: a view on toxicity-driven ADT interruption and combination treatment versus selective monotherapy in biochemical recurrence.","Not yet captured in this edition: a view on toxicity-driven ADT interruption and hormonal monotherapy versus combination treatment in biochemical recurrence.","Not yet captured in this edition: a remark on attribution of relayed commentary about trial design and potential practice change in biochemical recurrence.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","86 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are selective and do not establish the prevalence of any opinion among HCPs. Reposts, relayed discussions and repeated podcast/video formats are not independent clinical endorsements.","Some connected treatment-selection remarks are missing. Several social-media passages and parts of recorded discussions were not fully assessed, so additional views and consequential qualifications may be absent.","Discussion that does not name ARASTEP, or uses an unrecognized spoken variant, may be missing. Coverage of the clinical question is therefore not exhaustive.","Not every named contributor has a documented clinical role. A profile's stated specialty or credential is not independent confirmation, and dated practice associations do not establish current employment.","Unidentified recorded passages cannot be assigned to named participants from a program title, participant list or similar voice label.","Presenting and steering-committee involvement are descriptions made by the sources; they do not independently validate a view or increase its evidentiary weight.","The sources provide trial methods and prospective expectations, not ARASTEP efficacy or safety results. Observational signals, historical comparisons and estimates must not be substituted for its pending randomized answer.","The methods context comes from registry information and a protocol publication rather than a separately listed full protocol document. No exact regulatory label was available to establish an approved indication for this regimen.","Posting and publication dates locate statements, not trial readouts or changes of mind. Differences across cases and treatment settings should not automatically be called disagreement."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":3,"publication":1,"registry":1,"regulatory":0,"x_thread":9,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":17,"methods":2},"count":19,"evidence_window":{"end":"2026-01-09","start":"2024-01-26"},"retrieval_snapshot":"2026-10-31T14:37:15.158536Z","timeline":[{"count":2,"week":"2024-W04"},{"count":1,"week":"2024-W18"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W43"},{"count":2,"week":"2024-W46"},{"count":1,"week":"2025-W19"},{"count":3,"week":"2025-W20"},{"count":2,"week":"2025-W23"},{"count":1,"week":"2025-W35"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W02"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT05794906:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05794906:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:41216639","quote_policy":"no_derivatives"},{"id":"mcp:bluesky_thread:plc-fptm2gxhu5ik4zs4apgth6kv-3lxcqyt6qps27","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5fa930","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6f49fb","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:acf175","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1638992910044614659:b7ac80ab-359f-4c27-8b96-f74c37f915b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1640628971963392001:187b0ad5-4090-4125-a53a-493df92a4f9b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1655609261966204930:5d0e0b4e-2ec5-40be-b058-1c9e01f32d7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715682393326059537:c9ad1a19-c8ce-4691-b739-43fbded1bd17","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715703270906237394:18e3d1ee-d52d-4ca1-b6e9-6bf68e3b65cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716208558923030867:7a316f6c-c704-4104-93d7-a9440a4d003d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1727680941538091037:f5d3da28-35e9-4ca7-85f7-7d33e9427f48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1736740634206085345:416be347-4c18-4eb6-a3bb-b2f501aae41c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1746887504714760322:d54f74d4-596e-4c13-8809-eb2588c8781a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750661041510564314:5bd88be6-2220-4df6-8547-2aaef493f7f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750667074303856724:7d436516-3b72-4a2b-850d-4fd43745bd1c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750731984601534664:d7036a49-8f8e-4232-91e7-47e4a771ccfb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750911601450869000:a0f7fd05-c879-436f-90a5-dc49ed79c3b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1759571070477053993:8a759839-672f-4bd5-abf4-f1c823c4a9bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1769702829294309717:c53d97d5-c7aa-4802-9459-d612aded2899","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1786447468781097086:e569f6b3-d722-4414-af5b-1b2c89b9adcf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797612361487880196:e92371d2-7031-40c7-891f-10a08b4cc6bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797617125772992962:90eeb89a-f232-41f2-879e-cb21fe82db80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797719995171864689:44a78681-d61d-4129-827f-bd32fcaa2011","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1804277982535483719:1ddd8f2a-eeab-4354-9946-a8a710a5d7e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1818708282367733915:d9189ffe-270f-4e97-8f5b-aeef571504dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829579897058013199:16e2a99e-ef07-4ce2-a337-8219fc2282dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1839364366824521999:3133bf6b-f1ba-4b90-b336-8cd448250274","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1849518755526660428:21636c5e-e194-408d-972e-265d5e4f8ada","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1857742788936479037:588b0d07-91b5-4bd3-82d7-bbe3412296c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1857757063088308305:a6d92fc0-3981-42de-b9a8-e41ed2d3b152","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882073343030907036:0cb12589-a82d-4b8e-91ad-9333426547d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1889698576344740243:06101b12-a3db-450c-93a0-5b3abab36109","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1891971055427666130:ebf357b6-fbfe-4d0b-ae1d-48c6f93e3bd3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1895519522976612583:2966b44b-e60e-4545-98d3-3efe602f4d63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1903839234756083969:8ad59812-58f7-42f9-8c47-2f6311e23451","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915828249961132082:9a17993b-232c-42af-b7a4-15b5ea9b1c04","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925250312018755890:d1de975a-04ed-4372-9a90-c0869219213f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929595173413016000:40689fd7-68c8-4ec4-a6d9-2f4b07e8280d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929877877928980876:fa9de1de-f103-4299-ad18-be292988607a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1930036771099713599:919a2a48-dc8a-4618-97c6-d681cc3fe0f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1930973088297922578:631cb710-3a63-41ed-b435-15492de6c7d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1936061620624449874:50c6c2b9-aa1d-4adf-ad07-54685de40b04","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938603041529155595:3a914276-127e-4095-af7b-b44c4291a773","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1943740362386026835:cc219b6c-5f3b-40ce-a5d1-fb4658eb48d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979186115845271866:4e0104b9-f921-4d3e-846d-f123c45f2261","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980550343516950695:d6144a26-ba56-4874-a662-6d5d3c296320","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991272110057259247:5067c9d5-e72b-401b-9df9-1c2f271b76fd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1994434819095237055:9abf5392-9d80-4cdd-8e3d-152a55bd498a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997731518278783469:adf930fe-73f2-4e80-8d5e-471e9f27905a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060923334838407610:d5c70314-4e32-41ef-ab7e-47e973e6b89d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084663204492226617:d2ede9eb-2eab-43c5-bd04-dcea10186cab","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:-s9OVBigJQQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:1QcupUS2C7o","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:GlQJnBeBTgc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Xqj0SmXyCOE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:sFRNrg8po_c","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":47,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":56},"count":56,"evidence_window":{"end":"2026-08-04","start":"2023-03-23"},"retrieval_snapshot":"2026-10-31T14:37:15.158536Z","timeline":[{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W13"},{"count":1,"week":"2023-W19"},{"count":3,"week":"2023-W42"},{"count":1,"week":"2023-W47"},{"count":1,"week":"2023-W51"},{"count":1,"week":"2024-W03"},{"count":4,"week":"2024-W04"},{"count":1,"week":"2024-W08"},{"count":1,"week":"2024-W12"},{"count":1,"week":"2024-W18"},{"count":3,"week":"2024-W23"},{"count":1,"week":"2024-W25"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W35"},{"count":1,"week":"2024-W39"},{"count":2,"week":"2024-W43"},{"count":2,"week":"2024-W46"},{"count":1,"week":"2025-W04"},{"count":1,"week":"2025-W07"},{"count":1,"week":"2025-W08"},{"count":1,"week":"2025-W09"},{"count":1,"week":"2025-W12"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W19"},{"count":3,"week":"2025-W20"},{"count":1,"week":"2025-W21"},{"count":5,"week":"2025-W23"},{"count":1,"week":"2025-W25"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W28"},{"count":2,"week":"2025-W35"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W32"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Nubeqa"],"label":"darolutamide","slug":"darolutamide"},{"reason":"Unmapped registry intervention: placebo matching darolutamide","status":"unmapped"},{"reason":"Unmapped registry intervention: adt","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Biochemically Recurrent Prostate Cancer","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"ARASTEP","aliases":["ARASTEP","A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer"],"brief_title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Biochemically Recurrent Prostate Cancer"],"display_condition":"high-risk biochemical recurrence of prostate cancer","display_interventions":[["darolutamide"]],"enrollment":{"count":985,"type":"ACTUAL"},"interventions":[{"name":"Darolutamide (BAY1841788, Nubeqa)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Placebo matching darolutamide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"},{"name":"ADT","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"}],"nct_id":"NCT05794906","official_title":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2027-07-30","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Radiological progression-free survival (rPFS) by Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) assessed by Blinded independent central review (BICR)","timeFrame":"After randomization to after last treatment, approximately 24 months"}],"registered_date":{"date":"2023-04-03","type":"ACTUAL"},"registry_last_updated":"2026-07-07","registry_url":"https://clinicaltrials.gov/study/NCT05794906","short_name":"ARASTEP","short_name_basis":"registry_acronym","sponsor":"Bayer","start_date":{"date":"2023-04-03","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"21492","type":"sponsor_study_id"},{"domain":"CTIS (EU)","id":"2022-501343-33-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}